American Thoracic Society International Conference 2022 (ATS 2022)

Adolescents and adults with severe uncontrolled asthma while on inhaled corticosteroids (ICS) had greater responses to the human monoclonal antibody tezepelumab than placebo, according to prespecified exploratory results of the phase III NAVIGATOR trial.

Chronic obstructive pulmonary disease (COPD) is associated with an earlier diagnosis of lung cancer, according to a cross-sectional, real-world study.

A fixed-dose combination of albuterol and budesonide, delivered as needed, reduced the risk of severe exacerbations in patients with moderate-to-severe asthma inadequately controlled with corticosteroid maintenance therapy, according to results of the phase III MANDALA trial presented at ATS 2022.

Treatment with BI 1015550, a novel investigational phosphodiesterase 4 (PDE4) inhibitor, slows lung function decline in patients with idiopathic pulmonary fibrosis (IPF) with or without background antifibrotic therapy, according to a 12-week phase II trial data presented at ATS 2022.

In patients with non-small-cell lung cancer (NSCLC), image-guided thermal ablation (IGTA) via microwave ablation (MWA) appears to deliver better survival benefit compared with another IGTA subtype, radiofrequency ablation (RFA), or stereotactic body radiation therapy (SBRT), according to a systematic review and meta-analysis presented at ATS 2022.

In addition to cardiometabolic benefits, a lifestyle intervention aimed at weight loss in patients with chronic obstructive pulmonary disease (COPD) who are overweight or obese may reduce COPD symptoms, according to results of the INSIGHT COPD trial presented at ATS 2022.

The tyrosine kinase inhibitor imatinib may reduce mortality in patients hospitalized with severe COVID-19, according to follow-up results of the CounterCOVID study presented at ATS 2022.

Switching from triple therapy to dual bronchodilation improves symptom control in patients with chronic obstructive pulmonary disease (COPD) in a new analysis of the DACCORD study.

Findings from the open-label extension (OLE) phase of the INCREASE study boost the efficacy and safety of inhaled treprostinil for pulmonary hypertension due to interstitial lung disease (PH-ILD).